CIK 0001582313
- Large accelerated filer
Xenon Pharmaceuticals Inc.
Sign in to watch- Ticker
- XENE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- Operating
- EIN
- 980661854
- Phone
- +1 604-484-3300
- Business address
- 200 - 3650 GILMORE WAY, BURNABY, British Columbia, Canada
- Open-market buys, last 90 days
- $1,681,140
- in 2 filings
- Open-market sales, last 90 days
- $425,829
- in 1 filing, $426K under 10b5-1 plans
Net +$1,255,311. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-07 | EMPFIELD JAMES R. EVP, Drug Discovery | Exercise or conversion · Stock Option (Right to Buy) | −2,500 | 0 | ||
| 2022-03-07 | EMPFIELD JAMES R. EVP, Drug Discovery | Exercise or conversion · Stock Option (Right to Buy) | −40,000 | 0 | ||
| 2022-03-04 | PIMSTONE SIMON N. Director | Exercise or conversion | +10,288 | $3.67 | $38K | 220,474 |
| 2022-03-04 | PIMSTONE SIMON N. Director | Shares withheld for taxes | −963 | $31.42 | $30K | 219,511 |
| 2022-03-04 | PIMSTONE SIMON N. Director | Sale | −4,532 | $30.66 | $139K | 214,979 |
| 2022-03-04 | PIMSTONE SIMON N. Director | Sale | −4,793 | $30.56 | $146K | 210,186 |
| 2022-03-04 | PIMSTONE SIMON N. Director | Exercise or conversion · Stock Option (Right to Buy) | −10,288 | 0 | ||
| 2022-03-04 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Exercise or conversion | +1,234 | $3.67 | $5K | 33,466 |
| 2022-03-04 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Shares withheld for taxes | −696 | $31.42 | $22K | 32,770 |
| 2022-03-04 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Exercise or conversion | +6,172 | $3.67 | $23K | 38,942 |
| 2022-03-04 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Sale | −6,710 | $30.56 | $205K | 32,232 |
| 2022-03-04 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Sale | −5,000 | $30.15 | $151K | 27,232 |
| 2022-03-04 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Sale | −5,000 | $31.05 | $155K | 22,232 |
| 2022-03-04 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Sale | −5,000 | $30.23 | $151K | 17,232 |
| 2022-03-04 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Exercise or conversion · Stock Option (Right to Buy) | −1,234 | 0 | ||
| 2022-03-04 | ROBIN SHERRINGTON EVP, Strategy & Innovation | Exercise or conversion · Stock Option (Right to Buy) | −6,172 | 0 | ||
| 2022-03-04 | EMPFIELD JAMES R. EVP, Drug Discovery | Exercise or conversion | +25,000 | $8.40 | $210K | 35,000 |
| 2022-03-04 | EMPFIELD JAMES R. EVP, Drug Discovery | Shares withheld for taxes | −6,685 | $31.42 | $210K | 28,315 |
| 2022-03-04 | EMPFIELD JAMES R. EVP, Drug Discovery | Sale | −18,315 | $30.79 | $564K | 10,000 |
| 2022-03-04 | EMPFIELD JAMES R. EVP, Drug Discovery | Exercise or conversion · Stock Option (Right to Buy) | −25,000 | 0 |
Page 18 of 27 · 536 trades